OpenAlex 2.457 eser 73 yazar konusu
Çalışmalar
2.457 eser
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III,…
Akademisyenler
73 akademisyen
- CANAN ERSOY 40 yazar konusu
- RIFAT EMRAL 17 yazar konusu
- ŞEVKİ ÇETİNKALP 15 yazar konusu
- FATOŞ PINAR TOPSEVER 13 yazar konusu
- MEHMET SARGIN 11 yazar konusu
- OĞUZHAN DEYNELİ 11 yazar konusu
- SÜLEYMAN BALDANE 11 yazar konusu
- İRFAN NUHOĞLU 10 yazar konusu
- ÖMERCAN TOPALOĞLU 10 yazar konusu
- TEVFİK SABUNCU 9 yazar konusu
- AYŞEGÜL ATMACA 8 yazar konusu
- EREN GÜRKAN 8 yazar konusu